Recent Company News

• 07:40 AM ET Nov 06, 2025
  

  Silence Therapeutics reports Q3 EPS ($0.15) vs FactSet ($0.19) [5 est, ($0.40)-(0.09)] ($6.24, 0.00)

• 08:26 AM ET Oct 27, 2025
  

  StreetAccount Summary - US Pre-market trading

• 07:32 AM ET Oct 23, 2025
  

  Silence Therapeutics completes enrollment in SANRECO Ph 2 study of divesiran for polycythemia vera (PV) ($7.20, 0.00)

• 07:42 AM ET Aug 07, 2025
  

  Silence Therapeutics reports Q2 EPS ($0.19) vs FactSet ($0.13) [4 est, ($0.18)-(0.09)] ($5.32, 0.00)

• 04:02 PM ET Jun 12, 2025
  

  Silence Therapeutics presents additional phase 1 data on divesiran for the treatment of polycythemia vera ($5.59, 0.00)

• 08:05 AM ET May 08, 2025
  

  Silence Therapeutics reports Q1 EPS (20.0p) vs FactSet (11.8p) [6 est, (31.5)-(1.0p)] ($3.70, 0.00)

• 10:34 AM ET May 05, 2025
  

  StreetAccount M&A Summary: Week of 28-Apr

• 10:21 AM ET Apr 10, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (33 total)

• 10:25 AM ET Apr 09, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (697 total)

• 10:18 AM ET Apr 07, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1167 total)